Cosciens Biopharma Stock Probability of Future Stock Price Finishing Over 3.13
| CSCI Stock | 3.13 0.04 1.29% |
COSCIENS |
COSCIENS Biopharma Target Price Odds to finish over 3.13
The tendency of COSCIENS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.13 | 90 days | 3.13 | more than 94.0 |
Based on a normal probability distribution, the odds of COSCIENS Biopharma to move above the current price in 90 days from now is more than 94.0 (This COSCIENS Biopharma probability density function shows the probability of COSCIENS Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days COSCIENS Biopharma has a beta of -0.13 suggesting as returns on the benchmark increase, returns on holding COSCIENS Biopharma are expected to decrease at a much lower rate. During a bear market, however, COSCIENS Biopharma is likely to outperform the market. Additionally COSCIENS Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. COSCIENS Biopharma Price Density |
| Price |
Predictive Modules for COSCIENS Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as COSCIENS Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of COSCIENS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
COSCIENS Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. COSCIENS Biopharma is not an exception. The market had few large corrections towards the COSCIENS Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold COSCIENS Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of COSCIENS Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.24 | |
β | Beta against Dow Jones | -0.13 | |
σ | Overall volatility | 0.35 | |
Ir | Information ratio | -0.13 |
COSCIENS Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of COSCIENS Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for COSCIENS Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| COSCIENS Biopharma generated a negative expected return over the last 90 days | |
| COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. | |
| The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| Latest headline from globenewswire.com: COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
COSCIENS Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of COSCIENS Stock often depends not only on the future outlook of the current and potential COSCIENS Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. COSCIENS Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.3 M |
COSCIENS Biopharma Technical Analysis
COSCIENS Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. COSCIENS Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of COSCIENS Biopharma. In general, you should focus on analyzing COSCIENS Stock price patterns and their correlations with different microeconomic environments and drivers.
COSCIENS Biopharma Predictive Forecast Models
COSCIENS Biopharma's time-series forecasting models is one of many COSCIENS Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary COSCIENS Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about COSCIENS Biopharma
Checking the ongoing alerts about COSCIENS Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for COSCIENS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| COSCIENS Biopharma generated a negative expected return over the last 90 days | |
| COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. | |
| The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| Latest headline from globenewswire.com: COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
Check out COSCIENS Biopharma Backtesting, COSCIENS Biopharma Valuation, COSCIENS Biopharma Correlation, COSCIENS Biopharma Hype Analysis, COSCIENS Biopharma Volatility, COSCIENS Biopharma History as well as COSCIENS Biopharma Performance. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.